UAC Seminar: Tove Fall & Máté Erdélyi

  • Date: –14:00
  • Location: Zoom: http://bit.ly/UACdec21
  • Lecturer: Tove Fall & Máté Erdélyi
  • Website
  • Organiser: Uppsala Antibiotic Center
  • Contact person: Eva Garmendia
  • Seminarium

Welcome to the UAC seminar series. Over the next occasions we will be presenting the science being done at UAC, featuring the projects and principal investigators that are part of our center.

Tove Fall: 'Impact of antibiotic treatment on microbiota and type 1 diabetes'

Antibiotic treatment may impact health, not only by promotion of antimicrobial resistance, but also through modulation of the normal microbiota, which could potentially impact immune-related disorders. In our project, we leverage register data on prescriptions and samples from cohort studies to investigate a) short- and long-term effects on oral and gut microbiota, and b) association of antibiotic treatment with development of type 1 diabetes.

Photo credit: Danish Saroee

Máté Erdélyi: 'Development of metallo-beta-lactamase inhibitors'

Our most common antibiotics are the β-lactam containing ones, such as the penicillins and cephalosporins. In response to their wide use, bacteria have acquired the ability to produce β-lactamases that inactivate β-lactam antibiotics. Metallo-β-lactamases are an especially problematic group of enzymes as these hydrolyze nearly all known β-lactam antibiotics, including carbapenems, which are our last resort drugs. There are very few known metallo-β-lactamase inhibitors, and none of them is clinically applicable.
In this talk I will show examples of our research on the development of metallo-β-lactamase inhibitors. These molecules are designed to protect β-lactam antibiotics and thereby allow their extended use in form of combination therapies. I will show examples for the design and synthesis of inhibitors of NDM-1, VIM-2 and CcrA, the evaluation of their bioactivities and the NMR spectroscopic determination of their protein binding site.